Lower fibroblast growth factor 23 levels in young adults with crohn disease as a possible secondary compensatory effect on the disturbance of bone and mineral metabolism

Journal of Clinical Densitometry

Volumn 17, Issue 1, 2014, Pages 177-184

  Oikonomou, Konstantinos A ^a,b   Orfanidou, Timoklia I ^b   Vlychou, Marianna K ^a   Kapsoritakis, Andreas N ^a   Tsezou, Aspasia ^a,b   Malizos, Konstantinos N ^a,b   Potamianos, Spyros P ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

Author keywords

25 hydroxy vitamin D (25OHD); Bone homeostasis; Bone mineral density (BMD); Crohn disease (CD); Fibroblast growth factor 23 (FGF 23)

Indexed keywords

25-HYDROXY VITAMIN D (25OHD); BONE HOMEOSTASIS; BONE MINERAL DENSITY (BMD); CROHN DISEASE (CD); FIBROBLAST GROWTH FACTOR 23 (FGF-23);

ADOLESCENT; ADULT; AGE FACTORS; BODY MASS INDEX; BONE DENSITY; CALCIFICATION, PHYSIOLOGIC; CASE-CONTROL STUDIES; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FEMUR; FIBROBLAST GROWTH FACTORS; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; VITAMIN D; YOUNG ADULT;

EID: 84894927821     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2013.03.019     Document Type: Article

References (27)

1. Ghishan F.K., Kiela P.R. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 2011, 300:G191-G201.
2. Leslie W.D., Miller N., Rogala L., Bernstein C.N. Body mass and composition affect bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Inflamm Bowel Dis 2009, 15:39-46.
3. Bernstein C.N., Leslie W.D. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol 2003, 15:857-864.
4. Tilg H., Moschen A.R., Kaser A., et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008, 57:684-694.
5. Rodríguez-Bores L., Barahona-Garrido J., Yamamoto-Furusho J.K. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol 2007, 13:6156-6165.
6. Berndt T., Thomas L.F., Craig T.A., et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A 2007, 104:11085-11090.
7. Kolek O.I., Hines E.R., Jones M.D., et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005, 289:G1036-G1042.
8. Razzaque M.S. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009, 5:611-619.
9. Marsell R., Jonsson K.B. The phosphate regulating hormone fibroblast growth factor-23. Acta Physiol (Oxf) 2010, 200:97-106.
10. Lu Y., Feng J.Q. FGF23 in skeletal modeling and remodeling. Curr Osteoporos Rep 2011, 9:103-108.
11. Kuro-o M. Overview of the FGF23-Klotho axis. Pediatr Nephrol 2010, 25:583-590.
12. Medici D., Razzaque M.S., Deluca S., et al. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol 2008, 182:459-465.
13. Katz S. Osteoporosis in patients with inflammatory bowel disease: risk factors, prevention, and treatment. Rev Gastroenterol Disord 2006, 6:63-71.
14. Oikonomou K., Kapsoritakis A., Eleftheriadis T., et al. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:1034-1045.
15. Stange E.F., Travis S.P., Vermeire S., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006, 55(Suppl 1):i1-i15. European Crohn's and Colitis Organisation.
16. Mowat C., Cole A., Windsor A., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011, 60:571-607. IBD Section of the British Society of Gastroenterology.
17. Best W.R., Becktel J.M., Singleton J.W., et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
18. Lewiecki E.M., Gordon C.M., Baim S., et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008, 43:1115-1121.
19. Yamamoto R., Minamizaki T., Yoshiko Y., et al. 1alpha,25-Dihydroxyvitamin D3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production invitro. J Endocrinol 2010, 206:279-286.
20. Alon U.S. Clinical practice. Fibroblast growth factor (FGF)23: a new hormone. Eur J Pediatr 2011, 170:545-554.
21. Leslie W.D., Miller N., Rogala L., Bernstein C.N. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol 2008, 103:1451-1459.
22. Sridharan M., Cheung J., Moore A.E., et al. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation. Calcif Tissue Int 2010, 87:398-405.
23. Yuan Q., Sato T., Densmore M., et al. FGF-23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH. J Bone Miner Res 2011, 26:2026-2035.
24. Marsell R., Mirza M.A., Mallmin H., et al. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int 2009, 20:1167-1173.
25. Mirza M.A., Karlsson M.K., Mellström D., et al. Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res 2011, 26:857-864.
26. Hill R.J., Brookes D.S., Davies P.S. Bones in pediatric Crohn's disease: a review of fracture risk in children and adults. Inflamm Bowel Dis 2011, 17:1223-1228.
27. Veerappan S.G., O'Morain C.A., Daly J.S., Ryan B.M. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:1261-1272.